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Abstract  
Background Congenital adrenal hyperplasia (CAH) is one of the most common monogenic 
autosomal recessive disorders with an incidence of 1 in 15 000. About 1 in 70 individuals in 
the general population are carriers of a severe CYP21A2 mutation. It has been suggested that 
this confers a survival advantage, perhaps as a result of increased activity in the 
hypothalamic–pituitary–adrenal axis. We investigated vulnerability to psychological stress in 
obligate carriers. 
Method The Swedish CAH Registry encompasses more than 600 patients. Parents, i.e., 
obligate carriers of the CYP21A2 mutation, were identified through the Multigeneration 
Register. The diagnosis of the child was used as the psychological stressor. Psychiatric 
diagnoses before and after the birth of a child with CAH were compared to those of controls 
derived from (i) the general population, (ii) parents of children with hypospadias, and (iii) 
parents of children with diabetes mellitus type 1 (T1DM).  
Results Parents of children with CAH had less risk of being diagnosed with any psychiatric 
disorder (OR, 0.6), an affective disorder (OR, 0.5) or substance misuse (OR, 0.5) after the 
diagnosis of the child, compared to the general population. Their risk was also decreased 
compared to parents of a child with hypospadias (OR, 0.6, 0.4 and 0.2, respectively) and 
parents of a child with T1DM (OR 0·7, 0·6 and 0·2, respectively). The CYP21A2 carriers had 
a lower risk of developing mood and stress-related disorders after the diagnosis of the child.  
Conclusion Obligate CYP21A2 carriers had a reduced risk of a psychiatric diagnosis and 
were less vulnerable to a psychologically stressful situation, at least with respect to receiving 
a psychiatric diagnosis. This indicates a better ability to cope with psychological stress among 
heterozygous carriers of severe CYP21A2 mutations, which may contribute to the apparent 
survival advantage.  
 3 
Introduction 
Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most 
common monogenic autosomal recessive disorders with an incidence of 1 in 10 000–20 000.1 
The incidence is even higher in some populations, e.g., 1/295 in Yupik Eskimos (classic 
CAH) and 1/27 in the Ashkenazi Jewish population (non-classic CAH).
2
 About 1 in 50 
individuals in the Swedish population are carriers of a mutation in the CYP21A2 gene and 1 in 
70 of a classic, more severe, CYP21A2 mutation.
3
 It has been suggested that being a carrier 
confers a survival advantage that could explain the relatively high frequency of the disease in 
most worldwide populations, similarly to the situation with sickle cell anemia where carriers 
have a survival advantage due to resistance to malaria. 
4,5,6
 
 
CAH results in varying degrees of cortisol and adrenalin deficiency. The severity of disease 
correlates with the severity of the CYP21A2 mutation. Clinically, CAH has been divided into 
the salt-wasting (SW), simple virilising (SV) and non-classic (NCAH) forms.
1
 Untreated, 
patients with the classic SW form develop lethal salt crises in the neonatal period while those 
with the SV form have a less pronounced risk of salt crisis. The cortisol deficiency leads to an 
increased pituitary ACTH production and results in increased synthesis of the steroid 
precursors prior to the enzyme block that are converted into androgens. Both SW and SV 
children with CAH result in virilisation of external genitalia at birth in children with 46,XX 
karyotype. The treatment consists of life long replacement therapy with hydrocortisone and in 
severe cases fludrocortisone. During periods of physical stress such as febrile illness the 
hydrocortisone dose must be adjusted. In contrast, patients with the less severe NCAH form 
escape salt crisis and affected females are not virilised at birth. Patients with NCAH often do 
not come to medical attention until they develop signs of androgen excess over time such as 
hirsutism or infertility. Men with NCAH remain largely undiagnosed.
7
 
 4 
 
There is a strong correlation between disease severity and CYP21A2 genotype based on the 
mildest allele.
8,9
 Deletions and mutations that completely abolish the enzyme activity in the 
homozygous form or in combination with the slightly less severe I2 splice mutation result in 
the most severe salt-wasting form of the disease. The I172N mutation is associated with the 
simple virilising form while V281L or P453S results in NCAH.
10
  
 
Although carriers of CYP21A2 mutations typically do not have clinical symptoms, increased 
androgen levels have been reported and their hypothalamic-pituitary-adrenal (HPA) axis is 
functionally affected.
4
 On ACTH stimulation, carriers respond with increased 17-
hydroxyprogesterone (17-OHP) levels, the metabolite prior to the enzyme block.
11
 
Interestingly, the cortisol response to ACTH stimulation has been shown to be more prompt 
and increased in carriers than in healthy controls.
4
 This increased efficiency of the HPA axis 
may be caused by an upregulated ACTH activity due to the relative deficiency in cortisol 
production and the resulting loss of negative feedback inhibition. One interpretation of these 
results would be that the carriers have fast and brisk response and a relatively quick down-
regulation of the cortisol synthesis. It has been hypothesised that this increased cortisol 
response, in response to stress, could enable a more rapid return to homeostasis and hence be 
advantageous.
4
 This almost doubled capacity to synthesise cortisol on acute stimulation could 
explain the proposed evolutionary advantage of being a carrier of a CYP21A2 mutation. 
 
It has been shown that CYP21A2 mutation carriers have a lower 24 hour urinary excretion of 
free cortisol.
5
 It has been hypothesized that the mild cortisol deficiency can result in a 
compensatory increase in hypothalamic CRH secretion. CRH is involved in the regulation of 
the HPA axis but also in other responses to stress such as the autonomic, immune, and 
 5 
behavioral responses. CRH is important for mood and anxiety since it interacts with the 
amygdala and modulates the monoaminergic system.
12,13
 It is known that cortisol and CRH 
are increased in anxiety and depression.
14,15,16
 Thus, an increased CRH level could have 
negative effects. It was therefore suggested that increased CRH may result in vulnerability to 
anxiety and depression by Charmandari and co-workers who showed that CRH stimulation in 
CYP21A2 carriers resulted in a higher peak ACTH. They report that a lower cortisol excretion 
and a higher ACTH response in 18 obligate CYP21A2 carriers and 16 controls were 
associated with a predisposition to obsessive-compulsive behavior as assessed by 
psychometric questionnaires.
5
 
 
The aim of this study was to investigate the vulnerability to psychological stress in obligate 
CYP21A2 mutation carriers, i.e, parents of children with CAH. We used the birth or diagnosis 
of an affected child as the stressor, and investigated whether CYP21A2 carriers had an 
increased risk for psychiatric morbidity per se and after this stressful event. Parents of 
children with hypospadias or diabetes mellitus type 1 (T1DM), both situations known to be 
stressful for the parents and having comparable aspects were used as controls.
17,18
 
 
 
Methods 
Subjects 
The Swedish National CAH Registry comprises more than 600 individuals and has been 
described in detail elsewhere.
3,19 
A complete personal identification number was known for 
545 of these patients born between 1910 and 2009, and the CYP21A2 genotype was known 
for more than 80%. An additional 43 patients were identified through the National Patient 
Register and validated as previously reported.
19
 Altogether, 588 patients with a 21-
 6 
hydroxylase deficiency were identified. All patients were anonymized by Statistics Sweden 
before the linkage to population based registers. 
 
Parents of patients with CAH were identified through the Multigeneration Register. They 
were then divided into two groups based on the genotype or the clinical severity of the disease 
of the child. The parents of individuals with SW or SV CAH were assumed to carry a classic 
CYP21A2 mutation. The other group comprised parents of patients with NCAH who may 
carry either a classic mutation or a mutation that would predict NCAH in addition to the 
parents of patients with CAH of unknown severity. A total of 610 carriers were identified and 
divided into two groups comprising 240 carriers of classic mutations and 370 carriers of a 
mixture of mutations and of undetermined severity. Three control groups of parents matched 
for age were used: parents from the general population (n=48,888), parents with a child 
diagnosed with hypospadias (n=22,294), and parents with a child diagnosed with T1DM 
(n=48,747).  
 
Study protocol 
The prevalence of psychiatric diagnoses in the different groups of parents previous to the birth 
of an affected child was investigated. The birth or diagnosis of the affected child was used as 
the psychological stressor. Psychiatric diagnoses of the parents before and after the birth of an 
affected child were analysed. The selected psychiatric diagnoses in the National Patient 
Register were mood disorders (ICD-8 codes 296.1, 296.3, 296.8, 300.4; ICD-9 codes 296, 
300E, 311; ICD-10 codes F30–F39), anxiety, dissociative, stress-related, somatoform, 
phobias or unspecified non-psychotic psychiatric diagnoses (ICD-8 code 300 except 300.4, 
code 307, ICD-9 code 300 except 300E, codes 306, 308-309; ICD-10 codes F40-F45, F48), 
eating disorders (ICD-9 codes 307B and 307F; ICD-10 code F50), mental and behavioral 
 7 
disorders due to psychoactive substance use (alcohol: ICD-8 codes 303; ICD-9 codes 303, 
305A and 305X; ICD-10 codes F10; other drugs: ICD-8 codes 304; ICD-9 codes 304; ICD-10 
codes F11–F19), and other behavioral emotional disorders with the onset usually occurring in 
childhood or adolescence (ICD-9 codes 312-313; ICD-10 codes F91-F98).   
 
A matched control design was used employing three different control groups with parents 
matched for sex and year of birth: (i) parents of children in the general population before and 
after the birth of the child, (ii) parents of children with diabetes type 1 (T1DM) (250 in ICD-
8/ICD-9 and E10 in ICD-10) before and after the diagnosis of the child, and (iii) parents of 
children with hypospadias (752.2 in ICD-8, 752.61 in ICD-9 and Q54 in ICD-10) before and 
after the birth of the child. Descriptive statistics are shown in Tables 1. Despite using the 
national registries it was not possible to identify matched controls for all parents resulting in a 
small variation in the number of parents in the different groups. 
 
All calculations were performed with and without controlling for the highest level of 
education reached by the parents. The educational level was designated as one of four 
different levels: primary and lower secondary school, upper secondary school, post-secondary 
school, postgraduate, or unknown level of education.  
The study was approved by the Regional Ethical Review Board in Stockholm, Sweden. 
 
Statistical analysis 
The risk of psychiatric disorders was estimated by conditional logistic regression. Results 
were reported as Odds Ratios (ORs) and 95% Confidence Intervals (95%CI). The CYP21A2 
carriers were compared with three different control groups as described above.  
 8 
Calculations were also performed as bivariate and multivariate analyses controlling for the 
level of education of the parents. All statistical analyses were conducted with SAS software 
(version 9.3; Cary, NC, USA). 
 
Results 
There was a decreased risk of receiving any type of psychiatric diagnosis when the total 
number of parents of children with CAH, regardless of severity, was analysed and compared 
with the controls groups before the birth or diagnosis of the child (Table 2).  On breaking 
down the analysis into different diagnoses, a difference in mood and anxiety disorders 
persisted compared to the general population and to parents of a child with hypospadias. After 
adjusting for the educational level, the difference remained statistically significant for any 
type of psychiatric disorder compared to all three control groups and for mood disorder 
compared to the general population, as well as for anxiety disorders compared to parents with 
hypospadias. As seen in Table 3, after the birth of the child the risk of receiving any 
psychiatric diagnosis and of suicide, mood disorder, anxiety, substance misuse, or stress 
disorder was decreased for the CYP21A2 carriers in all comparison groups except for anxiety 
compared to T1DM (OR 0.3–0.8).  
 
The parents of children with classic CAH, i.e., obligate carriers of a classic, more severe, 
CYP21A2 mutations, were also analysed separately. The difference in the risk between the 
groups receiving any psychiatric diagnosis before the birth of the child only reached statistical 
significance when compared to parents with a child with hypospadias (Table 4). After the 
diagnosis of a child, there were significant differences indicating a lower risk of receiving 
several psychiatric diagnoses for the carriers (Table 5).  The carriers of classic CYP21A2 
mutations had a lesser risk of receiving any type of psychiatric diagnosis than parents in the 
 9 
general population (OR 0.6, 95%CI 0.4–0.9, p=0.014) or compared to a child with T1DM (OR 
0.6, 95%CI 0.4–0.9, p=0.017) or a child with hypospadias (OR 0.6, 95%CI 0.4–0.9, p=0.007). 
They were less likely to have a diagnosis of mood disorder/affective disorder after the 
diagnosis of the child, compared to the general population (OR 0.4, 95%CI 0.2–0.9, p=0.0164) 
or a child with hypospadias (OR 0.4, 95%CI 0.2–0.8, p=0.013). The carriers were less likely 
to develop substance misuse (including drugs and alcohol misuse) compared to all three 
control groups (OR 0.2–0.3, p≤0.02). When analysed separately, alcohol misuse showed a 
significant difference compared to that of the parents with a child with T1DM and a tendency 
towards that of the general population or hypospadias. The difference for anxiety disorder was 
significant compared to the general population, but did not reach significance for the T1DM 
and hypospadias parents on controlling for educational level. The difference for the risk of 
committing suicide was significant compared with that for the general population without 
adjusting for education, but in no other comparisons. 
 
Comparisons between the parents of children with NCAH or CAH of unknown severity, i.e., a 
mixture of carriers of both severe and milder CYP21A2 mutations, did not show significant 
differences in any of the parameters studied, only some tendencies, indicating that the severity 
of the mutation was important (data not shown).  
 
Statistical calculations for parents of girls and boys with CAH separately did not show 
significant differences between the different parental groups (data not shown), most probably 
due to small sample sizes. The same was true when mothers and fathers of children with 
severe mutations were assessed separately, whereby only a few parameters showed significant 
differences (data not shown), most likely due to sample size. 
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Discussion 
This is the largest study investigating carriers of a CYP21A2 mutation and is derived from a 
population-based cohort. We found that obligate carriers, i.e., parents of patients with known 
CAH, had a decreased risk of receiving a psychiatric diagnosis both per se, i.e., before and 
more markedly so after the birth of an affected child, regarded as a stressful event. The 
carriers were compared to three control groups: parents in the general population, parents of a 
child with T1DM, and parents of a child with hypospadias. These control groups were chosen 
to control for the type of stress that having a child with CAH may pose to the parents. The 
birth of a child with genital anomalies or even unclear sex at birth is a known psychological 
stressor, and posttraumatic stress disorders are increased among these parents.
17,20
 
Hypospadias and CAH affect genital development and may lead to uncertainty of gender 
assignment at birth.
17,21
 CAH and T1DM are both potentially life-threatening diseases 
21,22
 
that require daily treatment and extra attention from the parents, something that is well known 
to be stressful.  
 
In order to investigate whether the severity of the mutation was important, we analysed the 
parents who were obligate carriers of classic and less severe CYP21A2 mutations separately. 
Those who were carriers of a severe mutation had a lower risk of developing any psychiatric 
diagnosis after the birth of the affected child than parents from any of the three control 
groups. In addition, they had a decreased risk of being diagnosed with an affective disorder or 
substance misuse. Moreover, suicides were less prevalent in carriers, significantly so 
compared to general population. These effects were only seen for carriers of severe, i.e., 
classic CYP21A2 mutations and not for the group with unknown and milder mutations. 
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We interpret our results to show the carriers to be less vulnerable to the psychologically 
stressful situation of having a child with a severe diagnosis, possibly because of an increased 
psychological resilience. It is not possible to decipher the mechanism for this in this type of 
epidemiological study, but it can be speculated that it is associated with adaptive changes in 
the HPA axis or mechanisms involving locus coeruleus, the monoaminergic system, or the 
amygdala via CRH effects.
12,13
 
 
Impairments in the function of the HPA axis, e.g., as a result of chronic stress, are known to 
be important in the development of depression owing to a hyperactive HPA axis with elevated 
basal cortisol levels, disrupted diurnal cortisol secretion, and dysregulation in the HPA 
negative feedback system.
12,23
 Carriers of severe CYP21A2 mutations may be at decreased 
risk of developing affective disorders as a result of their prompt and more elevated response 
to ACTH.
4
 This may facilitate a more efficient return to homeostasis via a more effective 
feedback inhibition of cortisol on supra-hypothalamic, hypothalamic, and/or pituitary levels.
4
 
The picture is complicated, however, by the positive feed-forward mechanism where 
glucocorticoids further enhance CRH activity and behavioral responses to stress 
24
 that would 
result in the opposite.  
 
Interestingly, our findings are in contrast with the previous suggestion that CYP21A2 carriers 
are at increased risk of affective and anxiety disorders. The study by Charmandari et al.
 5
 was 
conducted on a small group of individuals but consisted of both psychological assessments 
and biochemical laboratory investigations including CRH stimulation. They saw no difference 
when the carriers and controls were compared on a group level, but correlations with the 
results of the different psychometric tests differed for the carriers and the healthy controls. An 
increased cortisol excretion correlated with more stress and anxiety in the controls, something 
 12 
that could be expected in stressful circumstances. The study had a considerable exclusion rate 
of 50%. The carriers were excluded for somatic or psychiatric reasons. CRH stimulation gave 
an area under the curve for ACTH that was larger in carriers than in controls, but the cortisol 
response showed no difference. Not surprisingly, the carriers had a larger area under the curve 
for 17-OHP.  
 
We used psychiatric diagnoses as a proxy or indicator for vulnerability to psychological 
stressors. By virtue of the study design, only associations can be identified, but not causal 
factors for the decreased risk for psychiatric morbidity. However, all comparisons point in the 
same direction, i.e., a lower risk of a psychiatric disorder whether related to stress, mood, 
anxiety, or suicide. Unfortunately, we were not able to specifically analyse obsessive-
compulsive disorder, stress-related disorders (e.g., PTSD) because of the low number of 
patients with the diagnosis.
25
 Our results point rather to a tendency towards a lower 
probability of receiving a diagnosis of anxiety in obligate carriers of a severe CYP21A2 
mutation. Unpredictable psychological stressors are more likely to result in depressive 
symptoms than predictable stressors.
26
 Is it possible that the exaggerated increase in the 
ACTH response is of greater importance than a smaller increase in CRH over time. 
 
The strengths of the study are that it covers a population-based cohort, implying no selection 
bias. The CAH Registry covers virtually all patients in Sweden and the National Patient 
Register used for controls and for the psychiatric diagnosis has full coverage since 1964 for 
hospital care and from 2001 for out-patient care. The CAH diagnosis was validated in the 
Registry, which was the basis for this epidemiological registry study using de-identified data, 
thus it is unlikely that patients were misdiagnosed. Less than 1% of CAH patients have a 
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spontaneously occurring mutation, i.e., one of the parents is not a carrier, but since this is a 
rare event, and therefore unlikely to affect our results.   
 
This study also provides interesting clues to our previous finding that psychiatric morbidity, 
more specifically substance misuse, anxiety, and mood disorders, is increased among patients, 
both men and women with CAH.
27,28
 Since there is high heritability for these psychiatric 
diseases, the finding that parents to patients with CAH have a decreased risk for psychiatric 
disorders suggests that the increased risk for psychiatric morbidity in patients with CAH is 
less likely to be genetically or socially determined. Hence, other factors related to the disease 
situation (e.g., psychological ones) are involved. 
  
In conclusion, our findings imply that CYP21A2 carriers have a decreased risk of any 
psychiatric diagnosis, especially affective and anxiety disorders. We compared parents of 
children with CAH, hypospadias, T1DM, and the general population and found that obligate 
CYP21A2 carriers seemed to be less vulnerable to the psychologically stressful situation of 
having a child with a chronic disease. This indicates a better ability to cope with 
psychological stress among heterozygous carriers of CYP21A2 mutations, which may 
contribute to a survival advantage and the relatively high incidence of CYP21A2 carriers seen 
worldwide. A possible advantage with respect to somatic stress related disorders needs to be 
investigated. 
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Table 1: Descriptive statistics for parents of children with CAH and their matched controls from general population, parents of 
children with type 1 diabetes or hypospadias. 
 
Comparison  1 Comparison  2 Comparison  3 
Probands Controls Probands Controls Probands Controls 
Characteristic 
Parents of children 
with CAH 
N=610   n (%) 
Parents from  
general population  
N=48,888 
n (%) 
Parents of children 
with CAH 
N=606  n (%) 
Parents of child 
with T1DM 
N=48,747  
 n (%) 
Parents of children 
with CAH 
N=577  n (%) 
Parents of child 
with hypospadias 
N=22,294 
n (%) 
Sex       
 Male 297 (48.7) 10404 (21.3) 305 (50.3) 37658 (77.3) 281 (48.7) 10820 (48.5) 
 Female 313 (51.3) 38484 (78.7) 301 (49.7) 11089 (22.7) 296 (51.3) 11474 (51.5) 
Age at child birth (yrs)       
 <35 489 (80.2) 41810 (85.5) 485 (80.0) 38294 (78.6) 475 (82.3) 17387 (78.0) 
 ≥35 121 (19.2) 7078 (14.5) 121 (20·0) 10453 (21.4) 102 (17.7) 4907 (22.0) 
Education    
 Primary and lower 
secondary 
125 (20.5) 11292 (23.0) 123 (20.3) 11621 (23.8) 112 (19.4) 4769 (21.4) 
 Upper secondary 248 (40.7) 21300 (43.6) 247 (40.8) 21804 (44.7) 245 (42.5) 10052 (45.0) 
 Post-secondary 73 (12.0) 6006 (12.3) 73 (12.0) 5357 (11.0) 72 (12.5) 2777 (12.5) 
 Postgraduate 148 (24.2) 8984 (18.4) 148 (24.4) 8075 (16.5) 140 (24.2) 4315 (19.4) 
 Unknown 16 (2.6) 1306 (2.7) 15 (2.5) 1890 (3.9) 8 (1.4) 381 (1.7) 
 Table 2. Odds ratios (with 95% confidence interval) and p-values for receiving a psychiatric diagnosis before the childbirth in parents 
of children with all types of CAH compared to matched parents of a child from the general population, parents of  a child with type 1 
diabetes or parents of  a child with hypospadias. 
Psychiatri
c disorder 
Bivariate analysis Multivariate analysis # 
Control group Control group 
Parents from  
general population 
Parents of child 
with T1DM 
Parents of child 
with hypospadias 
Parents from  general 
population 
Parents of child with 
T1DM 
Parents of child with 
hypospadias 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Adjusted OR 
(95% CI) 
p 
Adj OR 
(95% CI) 
p 
Adj OR 
(95% CI) 
p 
Any 
psychiatric 
diagnosis 0.5 (0.3-0.9) 0.016 0.4 (0.2 -0.8) 0.015 0.4 (0.2-0.8) 0.006 0.5 (0.3-0.9) 0.020 0.5 (0.2-0.9) 0.019 0.4 (0.2-0.8) 0.008 
 
Suicide 0.7 (0.3-1.6) 0.387 1.0 (0.4 -2.2) 0.943 0.7 (0.3-1.6) 0.422 0.7 (0.3-1.6) 0.406 1.0 (0.5-2.3) 0.918 0.8 (0.3-1.7) 0.491 
Mood 
disorder 0.1 (0.0-0.9) 0.044 0.2 (0.0 -1.6) 0.131 0.2 (0.0-1.1) 0.061 0.1 (0.0-1.0) 0.046 0.2 (0.0-1.6) 0.130 0.2 (0.0-1.1) 0.061 
 
Anxiety 0.4 (0.1-1.0) 0.056 0.4 (0.1 -1.1) 0.084 0.4 (0.1-1.0) 0.040 0.4 (0.1-1.0) 0.058 0.4 (0.1-1.2) 0.101 0.4 (0.1-1.0) 0.048 
Substance 
misuse 0.6 (0.2-1.7) 0.363 0.4 (0.1 -1.4) 0.157 0.6 (0.2-1.5) 0.265 0.7 (0.2-1.8) 0.408 0.5 (0.2-1.5) 0.201 0.6 (0.2-1.6) 0.323 
Drug 
Misuse 0.3 (0.0-2.5) 0.290 0.3 (0.0 -2.4) 0.271 0.4 (0.0-2.5) 0.301 0.4 (0.1-2.6) 0.312 0.4 (0.1-2.6) 0.310 
†  
Alcohol 
misuse 0.7 (0.2-2.1) 0.479 0.4 (0.1 -1.7) 0.225 0.6 (0.2-1.9) 0.384 0.7 (0.2-2.2) 0.527 0.5 (0.1-1.9) 0.277 0.6 (0.2-2.0) 0.444 
Stress 
disorder 0.4 (0.1-1.6) 0.187 0.2 (0.0 -1.4) 0.112 0.3 (0.1-1.2) 0.084 0.4 (0.1-1.6) 0.188 0.2 (0.0-1.6) 0.130 0.3 (0.1-1.2) 0.089 
# Adjustment for education.†-Values for this OR and 95% CI were not possible to calculate due to zero values. Bold values indicate P < 0 .05. Italic values 
indicate P = 0 .05–0.099 
  
Table 3: Odds ratios (with 95% confidence interval) and p values for receiving a psychiatric diagnosis after the childbirth in parents of 
children with all types of CAH compared to matched parents of a child from the general population, parents of a child with type 1 
diabetes or parents of  a child with hypospadias. 
Psychiatri
c disorder 
Bivariate analysis Multivariate analysis # 
Control group Control group 
Parents from  
general population 
Parents of child 
with T1DM 
Parents of child with 
hypospadias 
Parents from  general 
population 
Parents of child with 
T1DM 
Parents of child with 
hypospadias 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Adjusted OR 
(95% CI) 
p 
Adjusted 
OR (95% 
CI) 
p 
Adj OR 
(95% CI) 
p 
Any 
psychiatric 
diagnosis 0.7 (0.5-0.9) 0.017 0.8 (0.6-1.0) 0.043 0.7 (0.5-1.0) 0.024 0.7 (0.6-1.0) 0.034 0.8 (0.6-1.0) 0.091 0.7 (0.6-1.0) 0.042 
 
Suicide 0.3 (0.1-0.8) 0.014 0.3 (0.1-0.9) 0.030 0.2 (0.0-0.7) 0.014 0.3 (0.1-0.8) 0.018 0.4 (0.1-1.0) 0.043 0.2 (0.0-0.7) 0.016 
Mood 
disorder 0.6 (0.4-0.9) 0.022 0.8 (0.5-1.2) 0.321 0.5 (0.3-0.9) 0.016 0.6 (0.4-1.0) 0.031 0.8 (0.5-1.3) 0.381 0.5 (0.3-0.9) 0.020 
 
Anxiety 0.6 (0.4-0.9) 0.016 0.7 (0.5-1.1) 0.173 0.6 (0.4-0.9) 0.021 0.6 (0.4-0.9) 0.024 0.8 (0.5-1.2) 0.228 0.6 (0.4-1.0) 0.034 
Substance 
misuse 0.5 (0.2-0.9) 0.020 0.3 (0.2-0.7) 0.002 0.5 (0.2-0.9) 0.024 0.5 (0.2-0.9) 0.030 0.4 (0.2-0.7) 0.003 0.5 (0.3-0.9) 0.034 
Drug 
Misuse 0.2 (0.1-1.0) 0.046 0.3 (0.1-1.0) 0.056 0.3 (0.1-1.1) 0.059 0.3 (0.1-1.0) 0.056 0.3 (0.1-1.1) 0.070 0.3 (0.1-1.1) 0.067 
Alcohol 
misuse 0.5 (0.3-1.1) 0.089 0.4 (0.2-0.8) 0.007 0.6 (0.3-1.2) 0.146 0.6 (0.3-1.2) 0.121 0.4 (0.2-0.8) 0.013 0.6 (0.3-1.3) 0.186 
Stress 
disorder 0.4 (0.2-0.9) 0.022 0.5 (0.2-1.0) 0.047 0.4 (0.2-0.8) 0.011 0.5 (0.2-0.9) 0.028 0.5 (0.3-1.0) 0.062 0.4 (0.2-0.8) 0.015 
# Adjustment for education.†-Values for this OR and 95% CI were not possible to calculate due to zero values. Bold values indicate P < 0 .05. Italic values 
indicate P = 0 .05–0.099. 
 
  
Table 4: Odds ratios (with 95% confidence interval) and p values for receiving a psychiatric diagnosis before the childbirth in parents 
of children with classic form of CAH (i.e. carriers of a severe CYP21A2 mutation) compared to matched parents of a child from the 
general population, parents of a child with type 1 diabetes or parents of a child with hypospadias. 
Psychiat
ric 
disorder 
Bivariate analysis Multivariate analysis # 
Control group Control group 
Parents from  
general population 
Parents of child with 
T1DM 
Parents of child 
with hypospadias 
Parents from  general 
population 
Parents of child 
with T1DM 
Parents of child with 
hypospadias 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Adj OR (95% 
CI) 
p 
Adj OR 
(95% CI) 
p 
Adj OR 
(95% CI) 
p 
Any 
psychiatri
c 0.5 (0.3-1.1) 0.079 0.5 (0.2-1.0) 0.056 0.5 (0.2-1.0) 0.039 0.5 (0.3-1.1) 0.088 0.5 (0.2-1.1) 0.069 0.5 (0.2-1.0) 0.047 
 
Suicide 0.7 (0.3-1.9) 0.513 1.1 (0.4-2.9) 0.909 0.8 (0.3-2.0) 0.581 0.7 (0.3-2.0) 0.529 1.2 (0.4-3.1) 0.781 0.8 (0.3-2.2) 0.662 
Mood 
disorder 0.2 (0.0-1.5) 0.113 0.3 (0.0-2.3) 0.253 0.2 (0.0-1.6) 0.131 0.2 (0.0-1.5) 0.118 0.3 (0.0-2.3) 0.251 0.2 (0.0-1.6) 0.132 
 
Anxiety 0.5 (0.1-1.4) 0.181 0.4 (0.1-1.5) 0.172 0.4 (0.1-1.3) 0.116 0.5 (0.1-1.4) 0.185 0.4 (0.1-1.6) 0.206 0.4 (0.1-1.3) 0.141 
Substanc
e misuse 0.7 (0.2-2.3) 0.597 0.5 (0.1-1.8) 0.268 0.5 (0.2-1.7) 0.292 0.7 (0.2-2.3) 0.617 0.5 (0.1-2.0) 0.321 0.6 (0.2-1.8) 0.361 
Drug 
misuse 0.5 (0.1-3.9) 0.545 0.5 (0.1-3.3) 0.441 0.4 (0.1-3.1) 0.410 0.6 (0.1-4.0) 0.559 0.5 (0.1-3.7) 0.509 
  
Alcohol 
misuse 0.7 (0.2-2.7) 0.574 0.4 (0.0-2.5) 0.300 0.5 (0.1-2.1) 0.349 0.7 (0.2-2.8) 0.597 0.4 (0.1-2.7) 0.336 0.6 (0.1-2.3) 0.414 
Stress 
disorder 0.3 (0.0-2.3) 0.250 
  
   0.999 0.3 (0.0-1.8) 0.172 0.3 (0.0-2.3) 0.260 - 0.999 0.3 (0.0-1.9) 0.185 
# Adjustment for education.†-Values for this OR and 95% CI were not possible to calculate due to zero values. Bold values indicate P < 0 .05. Italic values 
indicate P = 0 .05–0.099.  
Table 5: Odds ratios (with 95% confidence interval) and p values for receiving a psychiatric diagnosis after the childbirth in parents of 
children with classic form of CAH (i.e. carriers of a severe CYP21A2 mutation) compared to matched parents of a child from the 
general population, parents of a child with type 1 diabetes or parents of a child with hypospadias. 
Psychiatri
c disorder 
Bivariate analysis Multivariate analysis # 
Control group Control group 
Parents from  
general population 
Parents of child 
with T1DM 
Parents of child with 
hypospadias 
Parents from  
general population 
Parents of child 
with T1DM 
Parents of child with 
hypospadias 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Crude OR 
(95% CI) 
p 
Adj OR 
(95% CI) 
p 
Adj OR 
(95% CI) 
p 
Adj OR 
(95% CI) 
p 
Any 
psychiatric 
diagnosis 
0.6 (0.4-0.9) 0.014 0.6 (0.4-0.9) 0.017 0.6 (0.4-0.9) 0.007 
 
 
 
0.6(0.4-0.9) 
 
 
 
0.017 0.7(0.4-1.0) 0.030 0.6(0.4-0.9) 0.009 
 
Suicide 0.2 (0.1-1.0) 0.048 0.3 (0.1-1.1) 0.076 0.3 (0.1-1.1) 0.067 
 
0.2(0.1-1.0) 
 
0.051 0.3(0.1-1.2) 0.095 0.3(0.1-1.1) 0.075 
Mood 
disorder 0.4 (0.2-0.9) 0.016 0.6 (0.3-1.1) 0.085 0.4 (0.2-0.8) 0.013 
0.5(0.2-0.9) 0.019 
0.6(0.3-1.1) 0.101 0.4(0.2-0.8) 0.014 
 
Anxiety 0.5 (0.3-0.9) 0.022 0.6 (0.3-1.1) 0.105 0.5 (0.3-0.9) 0.026 
0.5(0.3-0.9) 0.027 
0.6(0.3-1.2) 0.135 0.4(0.1-1.1) 0.078 
Substance 
misuse 0.3 (0.1-0.8) 0.020 0.2 (0.1-0.6) 0.005 0.2 (0.1-0.7) 0.014 
0.3(0.1-0.8) 0.022 
0.2(0.1-0.7) 0.007 0.2(0.1-0.8) 0.016 
Drug 
misuse 
 
- 
 
0.999 
 
- 
 
0.999 
 
- 
 
0.999 
 
- 
 
0.999 
 
- 
 
0.999 
 
- 
 
0.999 
Alcohol 
misuse 0.4 (0.1-1.1) 0.075 0.3 (0.1-0.8) 0.018 0.3 (0.1-1.1) 0.067 
 
0.4(0.1-1.1) 
 
0.082 0.3(0.1-0.8) 0.024 0.4(0.1-1.1) 0.078 
Stress 
disorder 0.3 (0.1-0.8) 0.023 0.3 (0.1-0.9) 0.039 0.3 (0.1-0.8) 0.018 
 
0.3(0.1-0.9) 
 
0.027 0.3(0.1-1.0) 0.048 0.3(0.1-0.8) 0.020 
# Adjustment for education.†-Values for this OR and 95% CI were not possible to calculate due to zero values. Bold values indicate P < 0 .05. Italic values 
indicate P = 0 .05–0.099. 
 
